Charmacy Pharmaceutical Co (HKSE:02289) Net Income From Continuing Operations : HK$56 Mil (TTM As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Charmacy Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Charmacy Pharmaceutical Co's net income from continuing operations for the six months ended in Dec. 2023 was HK$27 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Dec. 2023 was HK$56 Mil.

Charmacy Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Charmacy Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Charmacy Pharmaceutical Co Net Income From Continuing Operations Chart

Charmacy Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

44.68

48.08

28.35

101.03

56.16

Charmacy Pharmaceutical Co Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Net Income From Continuing Operations	Get a 7-Day Free Trial														-3.44	24.19	77.98	28.82	27.34

Charmacy Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$56 Mil.

Charmacy Pharmaceutical Co (HKSE:02289) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » Charmacy Pharmaceutical Co Ltd (HKSE:02289) » Definitions » Net Income From Continuing Operations

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 235, Song Shan North Road, Longhu District, Guangdong Province, Shantou, CHN, 515041

Website

https://www.chmyy.com

Charmacy Pharmaceutical Co Ltd is a China-based pharmaceutical distributor. It distributes diversified pharmaceutical products to pharmaceutical distributors, retail pharmacies, hospitals, clinics, and health centers. The company's distribution network covers Southern China and surrounding areas including Fujian province. The firm offers Western medicines, Chinese patent medicines, healthcare products, Chinese medicine material and decoction pieces, medical devices, cosmetic products, and others. All the group's operations are located in China.

Executives

Jiangxi Pharmaceutical Investment Co., Limited	2101 Beneficial owner
Jiang Yao Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Jiang Xi Jiang Zhong Yi Yao Shang Ye Yun Ying You Xian Ze Ren Gong Si	2201 Interest of corporation controlled by you
Yao Chuanglong	2101 Beneficial owner
You Zeyan	2202 Interest of your spouse
Guang Zhou Bai Yun Shan Yi Yao Ji Tuan Gu Fen You Xian Gong Si	2201 Interest of corporation controlled by you
Guang Zhou Yi Yao Ji Tuan You Xian Gong Si	2201 Interest of corporation controlled by you
Guang Yao Bai Yun Shan Xiang Gang You Xian Gong Si	2101 Beneficial owner
Rays Capital Partners Limited	2102 Investment manager
Ruan David Ching Chi	2201 Interest of corporation controlled by you
Asian Equity Special Opportunities Portfolio Master Fund Limited	2101 Beneficial owner
Wang Yonghui	2101 Beneficial owner

Charmacy Pharmaceutical Co (HKSE:02289) Headlines

No Headlines